May 01, 2023 / 08:30PM GMT
Operator
Hello, ladies and gentlemen, and thank you for standing by. Welcome to the Travere Therapeutics Corporate Update Call.
I would now like to turn the call over to your host, Naomi Eichenbaum, Vice President of Investor Relations. Ms. Eichenbaum, Please go ahead.
Naomi Eichenbaum -
Thank you, Marjorie, and thank you all for joining us today. Earlier today, we issued a press release covering the top line results from the Phase III DUPLEX study evaluating sparsentan for the treatment of Focal Segmental Glomerulosclerosis, or FSGS. A copy of the press release, along with the slides that we will be reviewing on today's call are available on our website. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Joining Eric, will be our Chief Medical Officer, Dr. Jula Inrig; and our SVP of Research and Development, Dr. Bill Rote, will be available during the Q&A session.
Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the
Travere Therapeutics Inc Corporate Update Call Transcript
May 02, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers